Lupin

** Shares of Lupin LUPN.NS rise 1.5% to 1,966 rupees

** Pharmaceuticals co gets US FDA Approval for Phytonadione Injectable Emulsion, USP

** Phytonadione Injectable Emulsion is indicated for treatment of low blood clotting and vitamin K deficiency

** YTD, LUPN down 7% vs 14% gain in Nifty Pharma index .NIPHARM

(Reporting by Vijay Malkar)

(([email protected];))

Oct 8 (Reuters) - Lupin Limited LUPN.NS:

• LUPIN - RECEIVES FDA APPROVAL FOR PHYTONADIONE INJECTABLE EMULSION USP, 1 MG/0.5 ML

Source text: ID:nBSE3W5b7V

Further company coverage: LUPN.NS

(([email protected];;))

Lupin launched Formoflo-G MDI, a fixed-dose triple combination metered-dose inhaler for chronic obstructive pulmonary disease, in India on October 6, 2026 following approval from the Drug Controller General of India. The twice-daily, single-strength inhaler combined Glycopyrronium Bromide, Formoterol Fumarate and Fluticasone Propionate for the long-term management of moderate to severe COPD. It was the world's first fixed-dose triple combination MDI for COPD and targeted a population of more than 55 million people living with the disease in India. Lupin ranked second in the Indian respiratory therapy segment. It reported net sales of about Rs27,488 crore in the year to March, with India contributing 29% of product sales. Chronic therapies accounted for about 67% of its domestic sales in the June quarter. The company had more than 20 inhalation filings and had guided to 20 domestic launches in FY27.

Powered by Tijori

Oct 1 (Reuters) - Lupin Limited LUPN.NS:

• COMPLETION OF BUYBACK OF SHARES BY MULTICARE PHARMACEUTICALS PHILIPPINES

Further company coverage: LUPN.NS

(([email protected];))

Sept 28 (Reuters) - Lupin Limited LUPN.NS:

• RECEIVES TENTATIVE FDA APPROVAL FOR APIXABAN ORAL SUSPENSION 1.25MG/ML VIA 505(B)(2)

• TO MANUFACTURE APIXABAN ORAL SUSPENSION AT SOMERSET, NEW JERSEY FACILITY UPON FINAL APPROVAL

Further company coverage: LUPN.NS

(([email protected];))

** Shares of India's Lupin LUPN.NS fall 0.5% to 2,141.60 rupees

** Kotak Institutional Equities reiterates "add" on Lupin and maintains FV at 2,525 rupees

** Brokerages see uncertainty in the pharma company's margins due to lower sales of key generic drugs Tolvaptan and Mirabegron in Q2FY27

** Cuts LUPN's EPS estimates for FY27-29 by 1% to 8%

** Notes contributions from generics such as Apixaban505 and gSpiriva Respitmat could partially support FY29 profitability

** Kotak expects company's Ellipta inhaler franchise to drive stronger earnings and improve margins in FY30

** Lupin stock up 1.52%, YTD

(Reporting by Anushka Rajvedi in Bengaluru)

((mailto: [email protected]))

Lupin Limited LUPN.NS:

• LUPIN AND TENPOINT THERAPEUTICS ANNOUNCE STRATEGIC PARTNERSHIP TO COMMERCIALIZE YUVEZZI™ IN THE EUROPEAN UNION, THE UNITED KINGDOM, SWITZERLAND, NORWAY, AND ICELAND

Source text: ID:nPn4SH4Rda

Further company coverage: LUPN.NS

Lupin received final U.S. FDA approval for Pitolisant Tablets in 4.45 mg and 17.8 mg strengths, bioequivalent to Wakix for the indications in the approved labeling. The approval expanded Lupin's U.S. product portfolio, which accounted for 42% of product sales in FY26. Lupin's FY26 net sales were about ₹27,500 crore. Recent U.S. approvals included sodium zirconium cyclosilicate on 10 August and Sugammadex and Diazepam injections on 31 July.

Powered by Tijori

Aug 17 (Reuters) - Lupin Limited LUPN.NS:

• ANNOUNCES APPROVAL FROM U.S. FDA FOR PITOLISANT TABLETS

Further company coverage: LUPN.NS

(([email protected];;))

Lupin received U.S. FDA approval for sodium zirconium cyclosilicate for oral suspension in 5g and 10g packets, as a bioequivalent to AstraZeneca's Lokelma for treating hyperkalemia in adults. Lokelma had estimated annual U.S. sales of $568 million in the 12 months to June 2026. The U.S. accounted for 42% of Lupin's product sales in the first quarter of FY27. Lupin's FY26 net sales were about ₹27,500 crore.

Powered by Tijori

Aug 10 (Reuters) - Lupin Limited LUPN.NS:

• APPROVAL OF SODIUM ZIRCONIUM CYCLOSILICATE FOR ORAL SUSPENSION IN THE UNITED STATES

Source text: ID:nnAZN4TD0PL

Further company coverage: LUPN.NS

(([email protected];;))

July 31 (Reuters) - Lupin Ltd LUPN.NS:

• LUPIN - ANNOUNCES U.S. FDA APPROVAL AND LAUNCH OF SUGAMMADEX INJECTION IN THE UNITED STATES

Source text: ID:nNSE1YCrYq

Further company coverage: LUPN.NS

(([email protected];))

July 21 (Reuters) - Lupin Ltd LUPN.NS:

• LUPIN SPINS OUT TWO ONCOLOGY PROGRAMS TO KAVERI THERAPEUTICS TO ADVANCE ITS ONCOLOGY STRATEGY

• LUPIN - KAVERI TO OPERATE AS INDEPENDENT ENTITY LED BY CEO KRISTI JONES AND CMO ROBERT PIERCE

• LUPIN - KAVERI TO SEEK ADDITIONAL CAPITAL FOR CLINICAL DEVELOPMENT

• LUPIN: TO HAVE SIGNIFICANT EQUITY STAKE IN KAVERI, PROVIDE SEED FUNDING, AND GRANT THEM EXCLUSIVE RIGHTS TO PROGRAMS

Source text: ID:nCNW26ktFa

Further company coverage: LUPN.NS

(([email protected];;))

July 1 (Reuters) - Lupin Ltd LUPN.NS:

• LUPIN - ANNOUNCES EMA APPROVAL FOR NAMUSCLA PEDIATRIC INDICATION

Source text: ID:nNSE9pHGq9

Further company coverage: LUPN.NS

(([email protected];))

June 26 (Reuters) - Lupin Ltd LUPN.NS:

• LUPIN RECEIVES TENTATIVE APPROVAL FROM U.S. FDA FOR ENZALUTAMIDE TABLETS

Source text: ID:nCNWK3Klta

Further company coverage: LUPN.NS

(([email protected];))

June 17 (Reuters) - Lupin Ltd LUPN.NS:

• LUPIN- LAUNCHES AZILSARTAN MEDOXOMIL TABLETS IN THE UNITED STATES

Source text: ID:nnAZN4T2SZZ

Further company coverage: LUPN.NS

(([email protected];))

June 8 (Reuters) - Lupin Ltd LUPN.NS:

• LUPIN - COLLABORATES WITH LABORATORIOS ERN TO LAUNCH LUFORBEC (BECLOMETASONE/FORMOTEROL) PMDI IN SPAIN

Source text: ID:nNSE5RfCtd

Further company coverage: LUPN.NS

(([email protected];))

June 4 (Reuters) - Lupin Ltd LUPN.NS:

• LUPIN RECEIVES APPROVAL FROM U.S. FDA FOR RANLUSPEC™(RANIBIZUMAB) INJECTION

Source text: ID:nPn57Fg26a

Further company coverage: LUPN.NS

(([email protected];))

May 28 (Reuters) - Lupin Ltd LUPN.NS:

• LUPIN’S ANKLESHWAR FACILITY RECEIVES EIR FROM U.S. FDA

Further company coverage: LUPN.NS

(([email protected];;))

May 22 (Reuters) - Lupin Ltd LUPN.NS:

• LUPIN - RECEIVES CHINA APPROVAL FOR OSELTAMIVIR PHOSPHATE ORAL SUSPENSION

Source text: [ID:]

Further company coverage: LUPN.NS

(([email protected];))

May 13 (Reuters) - Lupin Ltd LUPN.NS:

• LUPIN - LUPIN RECEIVES U.S. FDA APPROVAL FOR FAMOTIDINE INJECTION, USP

Source text: ID:nnAZN4SW0AC

Further company coverage: LUPN.NS

(([email protected];))

** India's Lupin LUPN.NS posted a profit of 14.6 billion rupees ($154.5 million) in Q4, up 89% Y/Y

** Shares of LUPN down ~4% to 2,364.3 rupees, after gaining about 5% in the previous two sessions ahead of earnings

STRONG U.S. MOMENTUM, INDIA RECOVERY

** Macquarie ("outperform", TP:2,460 rupees) sees strong visibility on co's upcoming U.S. launches and the resilience of its well-established domestic business

** Morgan Stanley ("equal-weight", TP:2,386 rupees) says Q4 results were driven by strong growth in its U.S. business due to new product launches and steady base business expansion; says India business resilient, supported by healthy growth in key therapies

** Nomura ("buy", PT:2,580 rupees) says margin expansion was supported favorable currency movements and a recovery in India growth, although overhead costs rose partly due to expenses related to the VISUfarma acquisition

($1 = 94.4725 Indian rupees)

(Reporting by Devika Nair in Bengaluru)

(([email protected];))

May 7 (Reuters) - Lupin Ltd LUPN.NS:

• MARCH-QUARTER CONSOL NET PROFIT 14.6 BILLION RUPEES

• MARCH-QUARTER CONSOL TOTAL REVENUE FROM OPERATIONS 74.75 BILLION RUPEES

• DIVIDEND 18 RUPEES PER SHARE

Further company coverage: LUPN.NS

(([email protected];;))

May 5 (Reuters) - Lupin Ltd LUPN.NS:

• LUPIN - RECEIVES U.S. FDA APPROVAL FOR GLYCEROL PHENYLBUTYRATE ORAL LIQUID

Source text: ID:nBSE3DnMTs

Further company coverage: LUPN.NS

(([email protected];))

April 22 (Reuters) - Lupin Ltd LUPN.NS:

• LUPIN LAUNCHES DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS IN THE UNITED STATES

Source text: ID:nPn8H4D2Na

Further company coverage: LUPN.NS

(([email protected];;))

April 17 (Reuters) - Lupin Ltd LUPN.NS:

• INCORPORATES WHOLLY OWNED SUBSIDIARY LUPIN (THAILAND) LIMITED IN THAILAND ON APRIL 17, 2026

Source text: ID:nBSE2RP5Bv

Further company coverage: LUPN.NS

(([email protected];;))

April 10 (Reuters) - Lupin Ltd LUPN.NS:

• LUPIN - LAUNCHES DAPAGLIFLOZIN TABLETS IN THE UNITED STATES

Source text: ID:nnAZN4SQ8JK

Further company coverage: LUPN.NS

(([email protected];;))

April 8 (Reuters) - Lupin Ltd LUPN.NS:

• ANNOUNCES APPROVAL OF DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE TABLETS IN UNITED STATES

Further company coverage: LUPN.NS

(([email protected];;))

Lupin Ltd LUPN.NS:

• LUPIN - RECEIVES TENTATIVE APPROVAL FROM U.S. FDA FOR SUGAMMADEX INJECTION

Source text: [ID:]

Further company coverage: LUPN.NS

** Shares of Indian drugmaker Lupin LUPN.NS rise nearly 1% to 2366 rupees

** Co on Wednesday received tentative approval From U.S. FDA for Pitolisant tablets, to treat excessive daytime sleepiness in kids aged six and older people with narcolepsy

** Approval for Lupin's Pitolisant Tablets 4.45mg and 17.8 mg as bioequivalent to Wakix, co says

** More than 208,915 shares change hand by 11.11 am IST vs 30-day avg of 928,638 shares

** LUPN rated "buy" on avg by 35 analysts covering it; median PT at 2436 rupees

** YTD, LUPN up 11%

(Reporting by Komal Salecha in Bengaluru)

(([email protected]))